Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $3.27 billion. The enterprise value is $2.75 billion.
| Market Cap | 3.27B |
| Enterprise Value | 2.75B |
Important Dates
The last earnings date was Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 113.58 million shares outstanding. The number of shares has increased by 41.38% in one year.
| Current Share Class | 113.58M |
| Shares Outstanding | 113.58M |
| Shares Change (YoY) | +41.38% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 107.62% |
| Float | 108.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 427.98 |
| PB Ratio | 6.21 |
| P/TBV Ratio | 6.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.08, with a Debt / Equity ratio of 0.01.
| Current Ratio | 15.08 |
| Quick Ratio | 14.64 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -64.03% and return on invested capital (ROIC) is -40.53%.
| Return on Equity (ROE) | -64.03% |
| Return on Assets (ROA) | -37.78% |
| Return on Invested Capital (ROIC) | -40.53% |
| Return on Capital Employed (ROCE) | -49.17% |
| Weighted Average Cost of Capital (WACC) | 15.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.03M |
| Employee Count | 247 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +189.82% in the last 52 weeks. The beta is 2.12, so Immunome's price volatility has been higher than the market average.
| Beta (5Y) | 2.12 |
| 52-Week Price Change | +189.82% |
| 50-Day Moving Average | 23.70 |
| 200-Day Moving Average | 21.95 |
| Relative Strength Index (RSI) | 62.62 |
| Average Volume (20 Days) | 1,172,370 |
Short Selling Information
The latest short interest is 17.98 million, so 15.83% of the outstanding shares have been sold short.
| Short Interest | 17.98M |
| Short Previous Month | 17.24M |
| Short % of Shares Out | 15.83% |
| Short % of Float | 16.55% |
| Short Ratio (days to cover) | 14.95 |
Income Statement
| Revenue | n/a |
| Gross Profit | -206.23M |
| Operating Income | -260.47M |
| Pretax Income | -254.32M |
| Net Income | -254.32M |
| EBITDA | -257.69M |
| EBIT | -260.47M |
| Earnings Per Share (EPS) | -$2.49 |
Balance Sheet
The company has $520.00 million in cash and $4.74 million in debt, with a net cash position of $515.26 million or $4.54 per share.
| Cash & Cash Equivalents | 520.00M |
| Total Debt | 4.74M |
| Net Cash | 515.26M |
| Net Cash Per Share | $4.54 |
| Equity (Book Value) | 525.08M |
| Book Value Per Share | 4.63 |
| Working Capital | 502.74M |
Cash Flow
In the last 12 months, operating cash flow was -$208.79 million and capital expenditures -$10.29 million, giving a free cash flow of -$219.09 million.
| Operating Cash Flow | -208.79M |
| Capital Expenditures | -10.29M |
| Depreciation & Amortization | 2.78M |
| Net Borrowing | n/a |
| Free Cash Flow | -219.09M |
| FCF Per Share | -$1.93 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -41.38% |
| Shareholder Yield | -41.38% |
| Earnings Yield | -7.79% |
| FCF Yield | -6.71% |
Analyst Forecast
The average price target for Immunome is $36.31, which is 26.30% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $36.31 |
| Price Target Difference | 26.30% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 212.70% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Immunome has an Altman Z-Score of 24.82 and a Piotroski F-Score of 2.
| Altman Z-Score | 24.82 |
| Piotroski F-Score | 2 |